GLP1R and heart failure: The STEP‐HFpEF study investigating the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and obesity (body mass index [BMI] ≥30 kg/m2) showed larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss upon treatment with 2.4 mg per week semaglutide than placebo.1